Prostate cancer screening in low- and middle- income countries: the Mexican case

Lajous, Martín; Cooperberg, Matthew R.; Rider, Jennifer R.; Manzanilla-García, Hugo Arturo; Gabilondo-Navarro, Fernando; Rodríguez-Covarrubias, Francisco; López‐Ridaura, Ruy; Torres‐Sánchez, Luisa; Mohar, Alejandro

doi:10.21149/10373

Cited by 12 publications

(11 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…During this same year, there were an estimated 1.41 million cases and 486,836 deaths due to PC [3]. Increased public awareness and the ease of prostate-specific antigen (PSA) testing have led to PC being considered a public health priority in low-and middle-income settings [4]. In Latin America, the burden of PC follows the global trend [5], although with the existence of heterogeneity among the countries from this region [6].…”

Section: Introductionmentioning

confidence: 99%

Incidence, Mortality, and Trends of Prostate Cancer in Mexico from 2000 to 2019: Results from the Global Burden of Disease Study 2019

Beltran-Ontiveros

Fernandez-Galindo

Moreno-Ortiz

et al. 2022

Cancers

View full text Add to dashboard Cite

In 2019, the Global Burden of Disease (GBD) estimated that prostate cancer (PC) was the 16th most common cause of death globally in males. In Mexico, PC epidemiology has been studied by a number of metrics and over various periods, although without including the most up-to-date estimates. Herein, we describe and compare the burdens and trends of PC in Mexico and its 32 states from 2000 to 2019. For this study, we extracted online available data from the GBD 2019 to estimate the crude and age-standardized rates (ASR per 100,000 people) of the incidence and mortality of PC. In Mexico, PC caused 27.1 thousand (95% uncertainty intervals, 20.6–36.0 thousand) incident cases and 9.2 thousand (7.7–12.7 thousand) deaths in males of all ages in 2019. Among the states, Sinaloa had the greatest ASR of incidence, and Guerrero had the highest mortality. The burden of PC showed an increasing trend, although the magnitude of change differed between metrics and locations. We found both an increasing national trend and subnational variation in the burden of PC. Our results confirm the need for updated and timely estimates to design effective diagnostic and treatment campaigns in locations where the burden of PC is the highest.

show abstract

Section: Introductionmentioning

confidence: 99%

Incidence, Mortality, and Trends of Prostate Cancer in Mexico from 2000 to 2019: Results from the Global Burden of Disease Study 2019

Beltran-Ontiveros

Fernandez-Galindo

Moreno-Ortiz

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…In addition, official regulation on PCa-ED is ambitious and yet controversial. A recent insight of PCa-ED in Mexico was published by Lajous et al, and it's suggested that following the official normativity is challenging as Mexico probably lack the wanted infrastructure and resources to bear the extra burden of around 15 million men undergoing PCa-ED 18 . Following the authors' statements, we consider that outlining a PCa-ED national effort requires not only the PCP topics addressed here but also a collective endeavor along health institutions to provide a wider overview and determine the settings needed for this challenging situation.…”

Section: Discussionmentioning

confidence: 99%

Detección oportuna de cáncer de próstata en los médicos de primer contacto en México: estudio transversal

Basulto-Martínez¹,

Ojeda-Pérez²,

Velueta-Martínez³

et al. 2021

CIRU

View full text Add to dashboard Cite

Aim: This study aims to assess primary care physicians (PCPs) knowledge and skills regarding prostate cancer early detection (PCa-ED). Materials and methods: A survey about knowledge and skills of PCa-ED was delivered to PCP. Logistic regression analysis was conducted for the propensity of PCP to test prostatic specific antigen (PSA) on asymptomatic men. Results: The survey was completed by 170 PCP. Score on risk factors knowledge was 51.5 ± 15.7% a better score was not associated with conducting PCa-ED (p = 0.674). The 40.6% answered having an institutional program on PCa-ED and 86% having access to PSA testing. Testing PSA on asymptomatic men was found in 40%. Moreover, 61.2% do not performed any digital rectal examination for PCa-ED, and this was not associated with preventing factors such as lack of space, time, and assistance (p > 0.05). Fewer years in practice and being a family medicine resident were associated with a less likelihood of testing PSA in asymptomatic men. The only associated factor in the multivariable model was having access to PSA testing (odds ratio: 3.36 confidence interval 95% 1.54-7.30) p = 0.002). Conclusions: A low rate of PCP performs PCa-ED and using concepts outside evidence-based recommendations. A national program on PCa-ED and continuing medical education for PCP are a promising strategy to improve PCa-ED.

show abstract

“…De acuerdo a Lajous et al, "la factibilidad de la evaluación del APE no está disponible de manera amplia en los países en vías de desarrollo o de ingresos medios como es México", (5) lo cual aumenta el problema de la detección oportuna.…”

Section: Discussionunclassified

Cáncer de próstata en México: experiencia epidemiológica en el Nuevo Hospital Civil de Guadalajara “Dr. Juan I. Menchaca”

Rubí-López

Real-Cárabes

Magaña-Gutiérrez

et al. 2021

rmu

View full text Add to dashboard Cite

Objetivo: Conocer la epidemiología, tratamiento y seguimiento de pacientes con cáncer de próstata en el Nuevo Hospital Civil de Guadalajara “Dr. Juan I. Menchaca”. Materiales y métodos: Se realizó un estudio observacional, descriptivo y retrospectivo en el que se incluyeron 196 casos de pacientes con cáncer de próstata atendidos entre los años 2015 y 2020 en el Nuevo Hospital Civil de Guadalajara “Dr. Juan I. Menchaca”. Resultados: De los 196 casos estudiados la edad media de presentación fue de 72.02 años (±8.77), el 53.5% no cuenta con nivel básico de estudios, asimismo el 87.7% no tiene un empleo formal; el índice de masa corporal (IMC) promedio fue de 25.43 kg/m2 (±3.13), siendo el tabaquismo, hipertensión y diabetes mellitus los factores de riesgo más frecuentes; una media de antígeno prostático específico (APE) antes del tratamiento de 17.59 ng/ml. De los casos atendidos, el 31.07% fueron sometidos a cirugía, 55.05% se encuentran con bloqueo hormonal y 1.02% en vigilancia. Solo se presentaron 12 casos (6.12%) de defunción asociados a cáncer de próstata con un abandono en el seguimiento del 37.75% de la población estudiada. Limitaciones del estudio: Tamaño de muestra, estudio unicéntrico. Valor: Estudio reciente de epidemiología de cáncer de próstata en Guadalajara, Jalisco. Conclusiones: El cáncer de próstata en la población analizada muestra un alto grado de marginación sociocultural, así como factores de riesgo asociados que limitan la indicación de tratamientos con intención curativa; estos factores influyen en el seguimiento adecuado de los pacientes.

show abstract

Prostate cancer screening in low- and middle- income countries: the Mexican case

Cited by 12 publications

References 4 publications

Incidence, Mortality, and Trends of Prostate Cancer in Mexico from 2000 to 2019: Results from the Global Burden of Disease Study 2019

Incidence, Mortality, and Trends of Prostate Cancer in Mexico from 2000 to 2019: Results from the Global Burden of Disease Study 2019

Detección oportuna de cáncer de próstata en los médicos de primer contacto en México: estudio transversal

Cáncer de próstata en México: experiencia epidemiológica en el Nuevo Hospital Civil de Guadalajara “Dr. Juan I. Menchaca”

Contact Info

Product

Resources

About